Search Beyond News…

10x Genomics schedules its Q2 2026 earnings release for August 6, 2026, adding to a wave of life‑science and health‑tech companies announcing second‑quarter results

Executive summary: 10x Genomics announced it will report its second‑quarter 2026 financial results after the market close on August 6, 2026. The announcement sets the timeline for investors to assess the company’s revenue growth, product adoption, and cash position, which influences its valuation in the life‑science tools sector.

Who is involved: 10x Genomics (Nasdaq: TXG), its executive management, shareholders, and the Nasdaq exchange.

Likely next: On August 6, 2026 the company will publish its Q2 2026 earnings and hold a post‑release conference call; the market’s reaction will depend on the actual financial outcomes disclosed then.

The press release is a routine earnings‑date announcement, giving investors a fixed calendar point for the company’s upcoming financial disclosure. It reflects the typical quarterly reporting cadence among publicly traded life‑science technology firms, which often cluster their earnings releases in early August. No financial figures or guidance are provided in the notice, so market impact will depend on the actual results released on the announced date.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Sources

Browse the full archive →